Skip to main content

Find Clinical Trials

Home
Conditions
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL

Clinical trial condition

Newly Diagnosed MYC/BCL2 Double-expressor DLBCL

Explore clinical trials studying Newly Diagnosed MYC/BCL2 Double-expressor DLBCL. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Newly Diagnosed MYC/BCL2 Double-expressor DLBCL trial results

Active, Not Recruiting

Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL

NCT07538180

Conditions: Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Locations: Sun Yat-sen University Cancer Center Guangzhou, China

View Trial Details